Mechanisms of Anabolic Resistance in Older Humans

Overview

About this study

The purpose of this study is to determine how adipose tissue influences skeletal muscle function and anabolic response to exercise in older adults.

Continued efforts are needed to identify new ways to extend healthspan in older adults. Toward this goal, skeletal muscle is critical because of its role in mobility, metabolic health, and overall well-being.  The loss of muscle mass and function (sarcopenia) is a common feature of aging that is associated with poor outcomes. Sarcopenia is often accompanied by mitochondrial impairments, oxidative stress, and insulin resistance, which can lead to further deterioration of muscle health and metabolic disease. These phenotypes, along with the key role of skeletal muscle in macronutrient metabolism, have motivated initiatives to target skeletal muscle to improve health in older adults.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria: 

  • Men and women between the ages of 21-35 years

 Exclusion Criteria:

  • Diabetes or fasting plasma glucose ³126 mg/dL
  • Body mass index (BMI) ³ 30 kg/m2
  • Anemia (female subjects hemoglobin of < 11 g/dl and male subjects hemoglobin < 12 g/dl)
  • Active coronary artery disease or history of unstable macrovascular disease (unstable angina, myocardial infarction, stroke, and revascularization of coronary, peripheral or carotid artery within 3 months of recruitment)
  • Renal failure (serum creatinine > 1.5mg/dl)
  • Chronic active liver disease (AST > 144IU/L or ALT > 165IU/L)
  • Oral warfarin group medications or history of blood clotting disorders.
  • Smoking.
  • Pregnancy or breastfeeding.
  • Alcohol consumption greater than 2 glasses/day or other substance abuse.
  • Untreated or uncontrolled hypothyroidism.
  • Debilitating chronic disease (at the discretion of the investigators).

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Ian Lanza, Ph.D.

Open for enrollment

Contact information:

Rachel Passehl

(507) 255-8112

Passehl.Rachel@mayo.edu

More information

Publications

Publications are currently not available